U.S. FDA issues 7 observations to Natco Pharma's formulations unit in Hyderabad
The U.S. Food and Drug Administration (U.S. FDA) has issued seven observations to Natco Pharma's formulations facility in Kothur, Hyderabad.
The facility was inspected by the U.S. FDA from June 9-19. On conclusion, the company received seven observations in Form-483, Natco Pharma said on Thursday. The company said it is confident of addressing the observations within the stipulated timeline.
'The company remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally,' Natco Pharma said.
The U.S. FDA had in April 2024 issued a warning letter to the facility while raising quality concerns. The action followed an inspection and issue of eight observations in October 2023 by the regulator. The company then said the move may result in delay or withholding of pending product approvals from the site.
The facility is for oral solid dosages, including cytotoxic orals; cytotoxic injectables; and pre filled syringes. The focus product categories are oncology, gastroenterology, central nervous system and cardiology.
EOM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
12 hours ago
- The Hindu
Granules unit in Hyderabad, one of the largest globally for paracetamol API, under U.S. FDA scanner
Generic drugmaker Granules India's active pharmaceutical ingredients (API) manufacturing facility in Bonthapally, Hyderabad, has been issued an observation by the U.S. Food and Drug Administration (U.S. FDA). The Bonthapally facility is one of the world's largest single-site paracetamol API manufacturing plants by volume. Along with paracetamol APIs, the company has established Metformin and Guaifenesin API manufacturing plants in the same facility, Granules India said in an intimation to the stock exchanges on Friday. The U.S. FDA had inspected the facility, located in Sangareddy district, from June 16-20 and issued Form 483 with one observation. The company said it will respond to the observation within the stipulated time.
Business Standard
19 hours ago
- Business Standard
Natco Pharma receives seven observations from USFDA Following Inspection at Kothur Facility
Natco Pharma announced that its pharmaceutical manufacturing facility in Kothur, Hyderabad, has received seven observations from the United States Food and Drug Administration (USFDA) following a recent inspection. In a regulatory filing, the company stated that the USFDA conducted the inspection from 9 June to 19 June 2025. At the conclusion of inspection, the USFDA has issued a Form 483 with seven observations. Natco Pharma expressed confidence in addressing the observations within the stipulated timeline and reaffirmed its commitment to current Good Manufacturing Practices (cGMP) and the consistent supply of high-quality pharmaceutical products to global markets. NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The companys consolidated net profit increased 5.3% to Rs 406.60 crore on a 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24. The counter shed 0.98% to Rs 872.75 on the BSE.
Business Standard
21 hours ago
- Business Standard
Nifty climbs above 25,000 level; realty shares advance
The key domestic indices traded with significant gains in morning trade, showing resilience in the face of escalating tensions between Israel and Iran. Market sentiment, however, remains sensitive to global cues, including crude oil prices and other international developments. The Nifty traded above the 25,000 level and Sensex crossed 82,150 mark. Realty shares jumped after declining in the past three trading sessions. At 10:30 IST, the barometer index, the S&P BSE Sensex advanced 816.02 points or 1% to 82,176.13. The Nifty 50 index jumped 232.45 points or 94% to 25,015. In the broader market, the S&P BSE Mid-Cap index fell 0.65% and the S&P BSE Small-Cap index shed 0.54%. The market breadth was strong. On the BSE, 2,271 shares rose and 1,203 shares fell. A total of 183 shares were unchanged. IPO Listing: Shares of Oswal Pumps were currently trading at Rs 641.20 at 10:14 IST on the BSE, representing a premium of 4.43% compared with the issue price of Rs 614. The scrip was listed at 632, exhibiting a premium of 2.93% to the issue price. So far, the stock has hit a high of 646.25 and a low of 625.20. On the BSE, over 6.96 lakh shares of the company were traded in the counter so far. Buzzing Index: The Nifty Realty index advanced 1.26% to 1,005.30. The index declined 2.7% in the past three trading sessions. Macrotech Developers (up 1.8%), Godrej Properties (up 1.54%), Brigade Enterprises (up 1.47%), Phoenix Mills (up 1.06%), Prestige Estates Projects (up 1.01%), Anant Raj (up 0.66%), Oberoi Realty (up 0.62%), Sobha (up 0.37%) and DLF (up 0.19%) advanced. Stocks in Spotlight: TD Power Systems rose 1.10% after the company secured an order worth Rs 67 crore from a leading multinational corporation for the supply of components for traction motors meant for export. ITD Cementation India declined 1.68%. The company announced that it has secured two major contracts cumulatively valued at approximately Rs 960 crore, excluding GST. Natco Pharma shed 0.68%. Natco Pharma announced that its pharmaceutical manufacturing facility in Kothur, Hyderabad, has received seven observations from the United States Food and Drug Administration (USFDA) following a recent inspection.
